ELDN

Eledon is a clinical-stage, single-asset biopharma with zero product revenue and no path to it in the provided data — the entire value rests on tegoprubart (a CD40L antagonist) clearing a Phase 3 kidney-transplant trial that management says it still needs FDA alignment to even initiate. On fundamentals there is nothing to underwrite: FY2025 net loss of -$45.6M, ROE of -56.3%, an accumulated deficit of -$401M, and R&D up 27.5% to $66.3M. The headline 21% EPS 'improvement' is misleading — the loss narrowed only because of a $33.4M non-cash swing in warrant fair value tied to a lower stock price; true operating cash burn actually worsened from -$47.3M to -$62.3M.

The balance sheet looks superficially clean (liabilities/equity just 0.40x, current assets $136M against $18.3M current liabilities), but that liquidity is a countdown, not a moat. Against ~$62M annual operating burn, the ~$136M of current assets is roughly two years of runway — and that is before the cost of an as-yet-unfunded Phase 3. The 10-K is explicit about 'substantial capital requirements and the challenges we may face in raising capital,' and the financing history shows exactly how the gap gets filled: a 2025 offering of 19.7M shares plus 15.2M pre-funded warrants for $53.6M, on top of $133.5M raised in 2024. Shares outstanding jumped 26.7% in one year, and outstanding common warrants struck at $3.00 sit right below today's $3.95 — dilution is structural and ongoing.